What is Claimed is:

~~1. A composition for preparing a drug carrier, comprising:~~

~~a first mixture comprising:~~

~~300 to 3600 parts by weight of a hydrophilic polymer;~~

~~300 to 3600 parts by weight of tricalcium phosphate ($Ca_3(PO_4)_2$); and~~

~~100 to 1800 parts by weight of water-soluble dispersant; and~~

~~a second mixture comprising:~~

~~100 to 7200 parts by weight of a water-absorbing material, wherein the water-absorbing material has high cytocompatibility; and~~

~~10 to 1800 parts by weight of a divalent cationic salt.~~

~~2. The composition of claim 1, wherein the hydrophilic polymer is selected from the group consisting of a salt of alginatic acid, polyacrylic acid, gelatin, carboxymethyl cellulose (CMC), polyglutamatic acid (γ-PGA).~~

~~3. The composition of claim 1, wherein the tricalcium phosphate is α-phase tricalcium phosphate or β-phase tricalcium phosphate.~~

~~4. The composition of claim 1, wherein the water-soluble dispersant is selected from the group consisting of methyl cellulose (MC), carboxymethyl cellulose (CMC), hydroxyethyl cellulose (HEC) and hydroxypropyl methyl cellulose (HPMC).~~

~~5. The composition of claim 1, wherein the water-absorbing material is selected from the group consisting of hyaluronic acid (HA), sodium hyaluronate, collagen, gelatin and polydextrose, high moisture content and degradable property.~~

~~6. The composition of claim 1, wherein the divalent cationic salt is selected from the group consisting of calcium chloride ($CaCl_2$), calcium carbonate ($CaCO_3$), barium chloride~~

~~($BaCl_2$), strontium chloride ($SrCl_2$) and magnesium chloride ($MgCl_2$).~~

~~7. A composition for preparing a pharmaceutical composition, comprising:~~

~~the composition of claim 1; and~~

~~a drug.~~

~~8. The compostion of claim 7, wherein the drug is an anti-inflammatory drug or an antibiotic, wherein~~

~~the anti-inflammatory drug is selected from the group consisting of adalimumab, certolizumab, etanercept, golimumab, abatacept, tocilizumab, rituximab and infliximab; and~~

~~the antibiotic is selected from the group consisting of gentamicin, vancomycin, mezlocillin, cloxacillin, methicillin, cefalothin, lincomycin, polymyxin E, bacitracin and fusidic acid.~~

~~9~~1. A method for preparing a pharmaceutical composition ~~using,~~ the ~~composition of claim 1,~~ method comprising ~~following steps~~:

preparing a first mixture by uniformly mixing 300 to 3600 parts by weight of a hydrophilic polymer, 300 to 3600 parts by weight of tricalcium phosphate, and 100 to 1800 parts by weight of a water-soluble dispersant;

preparing a second mixture by uniformly mixing 100 to 7200 parts by weight of a water-absorbing material, and 10 to 1800 parts by weight of a divalent cationic salt, wherein the water-absorbing material has high biocompatibility, moisture content and degradable property ;

preparing a precursor mixture by uniformly mixing a drug and the first mixture in water; and

uniformly mixing the second mixture and the precursor mixture.

2. The method of claim 1, wherein the hydrophilic polymer is selected from the group consisting of a salt of alginatic acid, polyacrylic acid, gelatin, carboxymethyl cellulose (CMC), polyglutamatic acid (γ-PGA).

3. The method of claim 1, wherein the tricalcium phosphate is α-phase tricalcium phosphate or β-phase tricalcium phosphate.

4. The method of claim 1, wherein the water-soluble dispersant is selected from the group consisting of methyl cellulose (MC), carboxymethyl cellulose (CMC), hydroxyethyl cellulose (HEC) and hydroxypropyl methyl cellulose (HPMC).

5. The method of claim 1, wherein the water-absorbing material is selected from the group consisting of hyaluronic acid (HA), sodium hyaluronate, collagen, gelatin and polydextrose, high moisture content and degradable property.

6. The method of claim 1, wherein the divalent cationic salt is selected from the group consisting of calcium chloride ($CaCl_2$), calcium carbonate ($CaCO_3$), barium chloride ($BaCl_2$), strontium chloride ($SrCl_2$) and magnesium chloride ($MgCl_2$).

7. The method of claim 1, wherein the drug is an anti-inflammatory drug or an antibiotic, wherein

the anti-inflammatory drug is selected from the group consisting of adalimumab, certolizumab, etanercept, golimumab, abatacept, tocilizumab, rituximab and infliximab; and

the antibiotic is selected from the group consisting of gentamicin, vancomycin, mezlocillin, cloxacillin, methicillin, cefalothin, lincomycin, polymyxin E, bacitracin and fusidic acid.